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Abstract
De novo design seeks to generate molecules with required property profiles by vir-
tual design-make-test cycles. With the emergence of deep learning and neural gener-
ative models in many application areas, models for molecular design based on neural
networks appeared recently and show promising results. However, the new models
have not been profiled on consistent tasks, and comparative studies to well-established
algorithms have only seldom been performed. To standardize the assessment of both
classical and neural models for de novo molecular design, we propose an evaluation
framework, GuacaMol, based on a suite of standardized benchmarks. The benchmark
tasks encompass measuring the fidelity of the models to reproduce the property distri-
bution of the training sets, the ability to generate novel molecules, the exploration and
exploitation of chemical space, and a variety of single and multi-objective optimization
tasks. The benchmarking open-source Python code, and a leaderboard can be found
on https://benevolent.ai/guacamol.
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1 Introduction
De novo molecular design is a computational technique to generate novel compounds with
desirable property profiles from scratch.1,2 It complements virtual screening, where large vir-
tual compound libraries are pre-generated, stored, and then subsequently ranked on demand.
Virtual screening is particularly useful when the virtual compounds are readily available
(commercially, or in in-house screening collections), or easy to synthesize.3,4 Datasets sized
on the order of 1013 can be routinely screened under current computational constraints.5
However, this is only a tiny fraction of drug-like chemical space, which has an estimated
size anywhere between 1024 and 1060 possible structures.5,6 This number might be even
larger considering new modalities such as PROTACs.7 Efficient approaches to query larger
combinatorial spaces without full enumeration via similarity to given structures have been
reported.8–10 However, it is not straightforward to perform more complex, multi-objective
queries without enumerating substantial parts of the space.
In contrast, in de novo design, only a relatively small number of molecules is explicitly
generated, and chemical space is explored via search or optimization procedures. Thus, by
focusing on the most relevant areas of chemical space for the current multi-objective query,
de novo design algorithms can in principle explore the full chemical space, given any ranking
or scoring function.
In addition to established discrete models relying on molecular graphs,11–13 models for
de novo design based on deep neural networks have been proposed in recent years, and have
shown promising results.14,15 Unfortunately, validation methods for these generative models
have not been consistent. Comparative studies to established de novo design models have
not yet been performed. Furthermore, recent property optimization studies often focused on
easily optimizable properties, such as drug-likeness or partition coefficients.15–17 This makes
it difficult to understand the strengths and weaknesses of the different models, to assess which
models should be used in practice, and how they can be improved and extended further.
In other fields of machine learning, for example computer vision and natural language
2
processing, standardized benchmarks have triggered rapid progress.18,19 Similarly, we believe
that the field of de novo molecular design can benefit from the introduction of standardized
benchmarks. They allow for a straightforward survey and comparison of existing models, and
provide insight into the strengths and weaknesses of models, which is valuable information
to improve current approaches.
In this work, we introduce GuacaMol, a framework for benchmarking models for de novo
molecular design. We define a suite of benchmarks and implement it as a Python package
designed to allow researchers to assess their models easily. We also provide implementations
and results for a series of baseline models on https://benevolent.ai/guacamol.
2 Models for De Novo Molecular Design
De novo design approaches require three components: 1) molecule generation, 2) a way to
score the molecules, and 3) a way to optimize or search for better molecules with respect to
the scoring function.13 For scoring, any function that maps molecules to a real valued score
can be used, for example quantitative structure-activity relationships (QSAR) and quanti-
tative structure-property relationships (QSPR) models, structure-based models for affinity
prediction, heuristics for the calculation of physicochemical properties, and combinations
thereof for multi-objective tasks.
At the center of molecule generation and optimization strategies lies the choice of the
molecular representation, which determines the potential range of exploration of chemical
space. Molecules can be constructed atom-by-atom or by combination of fragments.13 They
can be grown in the context of a binding pocket,20–24 which allows for structure-based scor-
ing, or be constructed and scored using entirely ligand-based methods. Choosing a very
general representation of molecules for construction, such as atom-by-atom and bond-by-
bond building, allows for potentially exploring all of chemical space. However, without any
constraints or scoring defining what sensible molecules look like, such representations can
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lead to molecules which are very difficult to synthesize or potentially unstable, particularly in
combination with powerful global optimizers such as genetic algorithms (GAs).13,25 To alle-
viate this problem, different approaches were introduced to generate molecules using readily
available building blocks and robust reaction schemes (e.g. amide couplings), or fragments
derived from known molecules.13,26,27 This, however, may drastically limit the potentially ex-
plorable space. This compromise between realistic molecules and large explorable molecular
space is a major dilemma of de novo design.
A seemingly obvious solution is to add a contribution penalizing unrealistic molecules
to the scoring function. Unfortunately, it is not trivial to encode what medicinal chemists
would consider as molecules that are acceptable to take forward to synthesis.28,29 Instead of
defining what good molecules look like as rules, or in the form of a scoring function, machine
learning approaches represent an attractive alternative, because they are potentially able to
learn how reasonable molecules look from data.30,31
Machine learning has been used in chemoinformatics for at least 50 years to score
molecules (QSAR/QSPR applications), that is to predict properties given a structure.32
The inverse QSAR problem of predicting structures given target properties has received
less attention.33 However, recent advances in algorithms and hardware have made machine
learning models and particularly neural networks, which directly output molecular structures
tractable.30
Two early papers on generative models for molecules, first published as preprints, em-
ployed the simplified molecular-input line-entry system (SMILES) representation, which al-
lows for the representation of molecular graphs as a string, with parentheses and numbers
indicating branching points and ring closures.34 Go´mez-Bombarelli et al. proposed to use
variational auto-encoders (VAEs), which encode the SMILES representation of a molecule
into a latent, continuous representation in real space, and back.15 Optimization can then be
performed by gradient descent or Bayesian optimization in real space. Segler et al. intro-
duced the notion of transfer and reinforcement learning for molecule generation using recur-
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rent neural networks (RNNs) on SMILES. In particular, an RNN called Long Short-Term
Memory (LSTM)35 was employed. The neural networks were pretrained on a general corpus
of molecules, and then either fine-tuned on a small number of known actives, or coupled to
an external scoring function to drive the generation of molecules with desired properties,
e.g. activity against biological targets.14 Both papers pointed out the then lack of models
for direct graph generation, which is considerably harder than generating sequences. Gen-
erative models based on neural networks have since been further explored, with work on
VAEs,17,36–45 RNNs,46–58 generative adversarial networks (GANs),54,55,59,60 adversarial au-
toencoders (AAEs),61–64 and graph convolutional networks,16,57,60,65 using SMILES strings
or graphs to represent molecules.
Also, the first prospective studies using neural generative models for de novo design
have been published. Merk, Schneider and coworkers validated the SMILES-LSTM transfer
learning method14 by generating compounds 1-3 for nuclear receptors, which after synthesis
and testing showed micro- to nanomolar activity (see Figure 1).66,67
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Figure 1: Compounds 1-3, generated by a SMILES-LSTM model,14 were made and tested,
and showed micro- to nanomolar activity against the RXR and PPAR receptors.66,67
An important result about the space that pretrained neural models can explore was
recently published by Arus-Pous et al.68 They studied whether SMILES RNNs trained on
a small subset (0.1%) of GDB13, an enumerated molecule set, which covers all potentially
stable molecules up to 13 heavy atoms, could recover almost the full dataset after sampling
a sufficient number of compounds. They showed that the SMILES RNN was able to cover
(and thus explore) a large portion of the complete chemical space defined by GDB13, and
even generate molecules which were incorrectly omitted in the original GDB13.68
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3 Assessing De Novo Design Techniques
To profile models for de novo molecular design, we differentiate between their two main use
cases:
• Given a training set of molecules, a model generates new molecules following the same
chemical distribution;
• A model generates the best possible molecules to satisfy a predefined goal.
The collection of benchmarks we propose below assesses both facets defined here. In the
following we will refer to these two categories as distribution-learning benchmarks and goal-
directed benchmarks, respectively.
The two benchmark categories are evaluated independently to afford models as much
flexibility as possible without penalty, since there is no one-to-one correspondence between
distribution-learning and goal-directed tasks. For instance, some models are able to generate
optimized molecules without learning the chemical distribution first. Also, a model trained to
reproduce a chemical distribution may then employ different strategies to deliver optimized
molecules.
3.1 Distribution-learning benchmarks
Models for de novo drug design often learn to reproduce the distribution of a training set, or
use this training set to derive molecular fragments before generating targeted molecules. This
allows some model architectures to learn the syntax of molecules in the selected molecular
representation, and often accelerates the goal-directed tasks.
The distribution-learning benchmarks assess how well models learn to generate molecules
similar to a training set, which in this work is a standardized subset of the ChEMBL database
(see Appendix 8.1).69 We consider five benchmarks for distribution learning:
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3.1.1 Validity
The validity benchmark assesses whether the generated molecules are actually valid, i.e.
whether they correspond to a (at least theoretically) realistic molecule. For example, molecules
with an incorrect SMILES syntax, or with invalid valence, are penalized.
3.1.2 Uniqueness
Given the high dimensionality of chemical space and the huge number of molecules potentially
relevant in medicine, generative models should be able to generate a vast number of different
molecules. The uniqueness benchmark assesses whether models are able to generate unique
molecules — i.e., if a model generates the same molecule multiple times, it will be penalized.
3.1.3 Novelty
Since the ChEMBL training set represents only a tiny subset of drug-like chemical space,
a model for de novo molecular design with a good coverage of chemical space will rarely
generate molecules present in the training set. The novelty benchmark penalizes models when
they generate molecules already present in the training set. Therefore, models overfitting
the training set will obtain low scores on this task.
3.1.4 Fre´chet ChemNet Distance
Preuer et al. introduced the Fre´chet ChemNet Distance (FCD) as a measure of how close
distributions of generated are to the distribution of molecules in the training set.70 In the
context of drug discovery, the usefulness of this metric stems from its ability to incorporate
important chemical and biological features. The FCD is determined from the hidden repre-
sentation of molecules in a neural network called ChemNet trained for predicting biological
activities, similarly to the Fre´chet Inception Distance sometimes applied to generative models
for images. More precisely, the means and covariances of the activations of the penultimate
layer of ChemNet are calculated for the reference set and for the set of generated molecules.
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The FCD is then calculated as the Fre´chet distance for both pairs of values. Similar molecule
distributions are characterized by low FCD values.
3.1.5 KL divergence
The KL (Kullback-Leibler) divergence71
DKL(P,Q) =
∑
i
P (i) log
P (i)
Q(i)
(1)
measures how well a probability distribution Q approximates another distribution P . For
the KL divergence benchmark, the probability distributions of a variety of physicochemical
descriptors for the training set and a set of generated molecules are compared, and the
corresponding KL divergences are calculated. Models able to capture the distributions of
molecules in the training set will lead to small KL divergence values.
It has been noted that a lack of diversity of the generated molecules is an issue for a
few models for de novo design, in particular GANs.70,72 Other model classes do not suffer
from that problem.14 The KL divergence benchmark captures diversity to some extent, by
requiring the generated molecules to be as diverse as the training set with respect to the
considered property distributions.
3.2 Goal-directed benchmarks
The goal-directed optimization of molecules relies on a formalism in which molecules can
be scored individually. The molecule score reflects how well a molecule fulfills the required
property profile (sometimes also called multi-property objective/MPO). The goal is to find
molecules which maximize the scoring function.
Concretely, the models are asked to generate a given number of molecules with high scores
for a given function. The models have access to the scoring function and can iteratively
improve their best molecule guesses, without knowing explicitly what the scoring function
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calculates.
Here, by using robust and simple, but relevant scoring functions for molecular design,
we disentangle the problem of molecule optimization from the problem of choosing good
scoring functions, which has been highlighted many times in the context of de novo design
and virtual screening, and will not be the focus of this article.
In general, the function to optimize will be defined as the combination of one or several
functions, representing different molecular features such as:
• Structural features. Examples: molecular weight, number of aromatic rings, number
of rotatable bonds;
• Physicochemical properties. Examples: TPSA, logP;
• Similarity or dissimilarity to other molecules;
• Presence and absence of substructures, functional groups or atom types.
The majority of benchmarks presented in this work define complex combinations of such
features. In addition, some benchmarks fall into special categories:
3.2.1 Similarity
Similarity is one of the core concepts of chemoinformatics.73,74 It serves multiple purposes
and is an interesting objective for optimization. First, it is a surrogate for machine learning
models, since it mimics an interpretable nearest neighbor model. However, it has the strong
advantage over more complex machine learning (ML) algorithms that deficiencies in the
ML models, stemming from training on small datasets or activity cliffs, cannot be as easily
exploited by the generative models. Second, it is directly related to virtual screening: de novo
design with a similarity objective can be interpreted as a form of inverse virtual screening,
where molecules similar to a given target compound are generated on the fly instead of
looking them up in a large database. In the similarity benchmarks, models aim to generate
9
molecules similar to a target that was removed from the training set. Models perform well
for the similarity benchmarks if they are able to generate many molecules that are closely
related to a given target molecule. Alternatively, the concept of similarity can be applied to
exclude molecules that are too similar to other molecules.
3.2.2 Rediscovery
Rediscovery benchmarks are closely related to the similarity benchmarks described above.
The major difference is that the rediscovery task explicitly aims to rediscover the target
molecule, not to generate many molecules similar to it. Rediscovery benchmarks have been
studied in previous work.11,14
3.2.3 Isomers
For the isomer benchmarks, the task is to generate molecules that correspond to a target
molecular formula (for example C7H8N2O2). The isomers for a given molecular formula can
in principle be enumerated, but except for small molecules this number will in general be very
large. The isomer benchmarks represent fully-determined tasks that assess the flexibility of
the model to generate molecules following a simple pattern (which is a priori unknown).
These benchmarks have no direct application in drug discovery.
3.2.4 Median molecules
In the median molecules benchmarks, the similarity to several molecules has to be maximized
simultaneously; it is designed to be a conflicting task.25 Besides measuring the obtained top
score, it is instructive to study if the models also explore the chemical space between the
target structures.
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3.3 Measuring Compound Quality
In previous works, several authors have highlighted that unrestricted de novo design al-
gorithms can generate compounds which are potentially unstable, reactive, laborious to
synthesize, or simply unpleasant to the eye of medicinal chemists.12,13,75 Systems proposing
too many unsuitable compounds lose trust, and will not be accepted by medicinal chemists.
Unfortunately, explicitly encoding all the background knowledge medicinal chemists acquire
with experience as an exhaustive list of unstable or undesirable substructures is challenging,
if not impossible, due to the inherent subjectivity and context dependency — e.g. a toxicity
risk might be assessed differently in oncology and diabetology. QSAR models only cover this
background knowledge in a limited way.
Nevertheless, a de novo design benchmark would be incomplete without an assessment of
compound quality. Here, following previous work, we employ rule sets which were compiled
to decide whether compounds can be included into high-throughput screening (HTS) collec-
tions. It has to be noted though that these rules are controversial. Assuming that molecules
filtered out by these patterns are all unsuitable, and that all compounds passing the filters
are reasonable molecules, would be misguided. These filters are therefore taken as a high
precision, low recall surrogate measure - we know that a filtered out molecule is probably
bad, but we also know that our list of filters is incomplete.
We employ Walters’ rd filters implementation,76 using the SureChembl, Glaxo, PAINS
(all retrieved from ChEMBL69), and in-house rule collections, to calculate the compound
quality metrics. The rule collection is available in the Supporting Information.77
4 Methods
Our framework for benchmarking models for de novo design, GuacaMol, is available as an
open-source Python package and can be downloaded from the Internet at www.github.com/BenevolentAI/guacamol.77
GuacaMol provides user-friendly interfaces that allow researchers to couple their models to
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the benchmarking framework with minimal effort.
We selected five distribution-learning and twenty goal-directed benchmarks. The exhaus-
tive specifications and implementation details of the distribution-learning and goal-directed
benchmarks are given in Appendices 8.2 and 8.3, respectively.
For all chemoinformatics-related operations, such as handling or canonicalization78 of
SMILES strings, physicochemical property (logP, TPSA79) or similarity calculations, Gua-
caMol relies on the RDKit package.80
Several of the molecule generation approaches we studied require a training dataset.
ChEMBL 24 was used for this purpose.69 The generation of the dataset is discussed and
detailed in Appendix 8.1.
In addition to the introduction of a benchmark suite for generative chemistry, this paper
provides its evaluation over several baselines. The goal is to present a fair comparison of some
recent methods that seem to achieve state of the art results in the field. These have been
selected to represent a variety of methods, ranging from deep learning generative models to
established genetic algorithms and more recent Monte Carlo Tree Search (MCTS). Internal
molecule representation was also taken into account, so that methods using SMILES strings
were represented alongside others using a graph representation of atoms and bonds. For
completeness and to provide a lower bound on the benchmark scores, two dummy baselines,
performing random sampling and best of dataset-picking, are also provided. All the baseline
models assessed in this work are described in Appendix 8.4. Our implementation of those
models is available on GitHub.81
5 Results and Discussion
5.1 Distribution-learning benchmarks
Table 1 lists the results for the distribution-learning benchmarks. The random sampler model
is a useful baseline for comparison because it shows what scores can be expected for good
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Table 1: Results of the baseline models for the distribution-learning benchmarks
Benchmark Random sampler SMILES LSTM Graph MCTS AAE ORGAN VAE
Validity 1.000 0.959 1.000 0.822 0.379 0.870
Uniqueness 0.997 1.000 1.000 1.000 0.841 0.999
Novelty 0.000 0.912 0.994 0.998 0.687 0.974
KL divergence 0.998 0.991 0.522 0.886 0.267 0.982
FCD 0.929 0.913 0.015 0.529 0.000 0.863
models on the KL divergence and Fre´chet benchmarks. Unsurprisingly, its novelty score is
zero since all the molecules it generates are present in the dataset. The SMILES LSTM
model sometimes produces invalid molecules. However, they are diverse, as attested by the
uniqueness and novelty benchmarks, and closely resemble molecules from ChEMBL. The
Graph MCTS model is characterized by a high degree of valid, unique, and novel molecules.
Nevertheless, it is not able to reproduce the property distributions of the underlying training
set as precisely as the SMILES LSTM model. The AAE model obtains excellent uniqueness
and novelty scores. The molecules this model produces are, however, not as close to the
dataset as the ones generated by the SMILES LSTM model. ORGAN obtains poor scores
for all the distribution-learning tasks. More than half the molecules it generates are invalid,
and they do not resemble the training set, as shown by the KL divergence and FCD scores.
This might indicate mode collapse, which is a phenomenon often observed when training
GANs. The scores of the VAE model are not the best in any categories, but this model
consistently produced relatively good scores for all the tasks. Our findings indicate that
simpler generative models (VAE, LSTM) are more powerful than more complex models. This
is in accordance with similar results in the literature on text and molecule generation.17,82
SMILES strings and their depictions for molecules generated by all six baseline models
are available in the Supporting Information or on https://benevolent.ai/guacamol.
5.2 Goal-directed benchmarks
Table 2 and Figure 2 show the results for the goal-directed benchmarks. The model “Best
of Dataset” is a useful baseline, since it actually corresponds to a strategy based on virtual
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Table 2: Results of the baseline models for the goal-directed benchmarks
Benchmark Best of dataset SMILES LSTM SMILES GA Graph GA Graph MCTS
Celecoxib rediscovery 0.505 1.000 0.732 1.000 0.355
Troglitazone rediscovery 0.419 1.000 0.515 1.000 0.311
Thiothixene rediscovery 0.456 1.000 0.598 1.000 0.311
Aripiprazole similarity 0.595 1.000 0.834 1.000 0.380
Albuterol similarity 0.719 1.000 0.907 1.000 0.749
Mestranol similarity 0.629 1.000 0.790 1.000 0.402
C11H24 0.684 0.993 0.829 0.971 0.410
C9H10N2O2PF2Cl 0.747 0.879 0.889 0.982 0.631
Median molecules 1 0.334 0.438 0.334 0.406 0.225
Median molecules 2 0.351 0.422 0.380 0.432 0.170
Osimertinib MPO 0.839 0.907 0.886 0.953 0.784
Fexofenadine MPO 0.817 0.959 0.931 0.998 0.695
Ranolazine MPO 0.792 0.855 0.881 0.920 0.616
Perindopril MPO 0.575 0.808 0.661 0.792 0.385
Amlodipine MPO 0.696 0.894 0.722 0.894 0.533
Sitagliptin MPO 0.509 0.545 0.689 0.891 0.458
Zaleplon MPO 0.547 0.669 0.413 0.754 0.488
Valsartan SMARTS 0.259 0.978 0.552 0.990 0.040
Deco Hop 0.933 0.996 0.970 1.000 0.590
Scaffold Hop 0.738 0.998 0.885 1.000 0.478
Total 12.144 17.340 14.396 17.983 9.009
screening. It illustrates what minimal scores the models must obtain to have an advan-
tage over pure virtual screening. The Graph GA model obtains the best results for most
benchmarks. The other GA model, based on SMILES strings, is distinctly better than the
“Best of Dataset” baseline. However, especially for the similarity tasks, it scores lower than
Graph GA. The SMILES LSTM model nearly performs as well as the Graph GA model,
and outperforms it on three benchmarks. The Graph MCTS model performs worse than the
Figure 2: Results of the Goal-Directed Benchmarks.
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baseline selecting the best candidates from ChEMBL.
In addition to these benchmarks, we explored a set of simpler benchmarks, mainly around
physicochemical properties (e.g. logP and QED), which have been used as objectives in
previous work on neural generative models (see Appendix 8.5). However, we found that
these benchmarks were not very well suited to differentiate between different models when
appropriate baselines are employed.
BestChEBML GraphGA MCTS SMILESGA LSTM
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Figure 3: Quality of the molecules generated in the goal-directed benchmarks, assessed as
the ratio of molecules passing the considered quality filters.
To measure the quality of the generated molecules from the goal-directed benchmarks,
we gathered and analyzed the top 100 molecules from each task, and checked whether they
passed the quality filters described earlier (see Figure 3). We found that 77% of molecules
from the Best of ChEMBL baseline pass the filters. Also, the same ratio is achieved by the
LSTM model. The Graph GA, SMILES GA, and Graph MCTS produces 40%, 36%, and
22% high quality molecules, respectively. This higher performance of the neural network
based model could be explained by a transfer of the information the LSTM has learned
about the general properties of the molecules’ distribution to the goal-directed optimization.
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Overall, Graph MCTS was found to perform poorly, qualitatively and quantitatively,
in the distribution-learning and goal-directed benchmarks. This could indicate that the
search paradigm of starting with a single molecule at the root the search tree which is then
subsequently refined in a search tree, might not be as well suited for de novo design as
approaches based on populations of good compounds. In concordance with previous work,
the Graph GA performs extraordinarily well in optimization, due to its flexibility to make
very fine grained local edits to the compounds, based on a population. However, again
consistent with previous work, the GAs provide molecules of inconsistent quality, as it has
no inherent or pre-encoded knowledge about a molecular distribution.
The LSTM-based model performs slightly worse in the goal-directed benchmarks than the
Graph GA, however the compound quality is considerably higher, being on the same level as
the virtual screening baseline. This can be attributed to the transfer of learned information
from the pretraining to the specific optimization problems. Neural models therefore seem to
at least partially resolve the weaknesses of virtual screening and GAs, exhibiting both good
optimization performance and molecule quality.
SMILES strings and their depictions for molecules generated by the five baseline models
for each MPO are available in the Supporting Information or on https://benevolent.ai/guacamol.
6 Conclusions and Outlook
Recently, generative models for de novo molecular design based on neural networks have been
introduced, and have shown promising results. However, there has been a lack of consistency
in the evaluation of such models. The present work addressed this problem by introducing
GuacaMol, a framework to quantitatively benchmark models for de novo design. It aims to
provide a standardized way of assessing new models, and to improve comparability of the
models.
Our framework defines two evaluation dimensions. First, it assesses models for their
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ability to learn from a dataset of molecules and to generate novel molecules with similar
properties. Second, it evaluates the faculty of generative models to deliver molecules with
specific properties, which we encode as molecule scores.
We provided a suite of benchmarks compatible with the evaluation framework. It en-
compasses a wide range of tasks, designed to assess the flexibility of generative models. The
proposed suite comprises 5 benchmarks for the ability of generative models to learn distribu-
tions of molecules, 20 optimization benchmarks for the generation of molecules with specific
properties, and a metric for compound quality.
We evaluated a series of diverse baseline models. In terms of optimization performance,
the best model is a genetic algorithm based on a graph representation of molecules. The
second best optimizer is a recurrent neural network model that considers SMILES represen-
tations of molecules. Both models achieve similar scores, which indicates that deep learning
models can reach the optimization performance of gold-standard discrete algorithms for de
novo molecular design. However, when pre-trained on large datasets, the neural model
outperforms the genetic algorithm in regards to compound quality.
The evaluation of the proposed benchmark suite for the baseline models pointed out
that some benchmark tasks can be too easily solved by most of the models. This indicates
the necessity of harder tasks for benchmarking models for de novo molecular design in the
future.
An important aspect that will need further focus is the quality of the generated molecules,
which is difficult to measure objectively. Furthermore, depending on the requirements, time
constraints or sample efficiency of different models can become important, and will require
further attention. Also, more work is needed to move neural models from SMILES to graph
representations, even though SMILES have been unreasonably effective.17 We are confident
that the flexible open source framework presented herein will enable and inspire the com-
munity to come up with even more challenging benchmarks for de novo design, so that
researchers can rigorously assess their models, and computational chemists can confidently
17
harness models with well-understood strengths and limitations.
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8 Appendix
8.1 Dataset Generation
The datasets used for training generative models are derived from the ChEMBL 24 database.69
The advantage of ChEMBL is that it contains only molecules that have been synthesized and
tested against biological targets. Other datasets, such as ZINC,3 contain, at least to some
degree, virtual molecules that are likely to be synthesizable, but have not been made yet.
Furthermore, ZINC is biased towards smaller and more readily synthesizable molecules, in-
dicated by a larger proportion of molecules containing amide bonds compared to ChEMBL.
The QM9 set,83 which is a subset of GDB9,6 is a completely enumerated dataset, which
has shown to be of value in many applications. However, since it contains mostly com-
pounds which have not been made yet, including many molecules with complex annulated
ring systems, it is not very well suited to learn representations of drug-like, synthesizable
molecules.
To generate the final dataset for the benchmarks, ChEMBL is post-processed by
1. removal of salts;
2. charge neutralization;
3. removal of molecules with SMILES strings longer than 100 characters;
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4. removal of molecules containing any element other than H, B, C, N, O, F, Si, P, S, Cl,
Se, Br, and I;
5. removal of molecules with a larger84 ECFP4 similarity than 0.323 compared to a hold-
out set consisting of 10 marketed drugs (celecoxib, aripiprazole, cobimetinib, osimer-
tinib, troglitazone, ranolazine, thiothixene, albuterol, fexofenadine, mestranol). This
allows us to define similarity benchmarks for targets that are not part of the training
set.
The post-processed ChEMBL dataset can be downloaded from the Internet.85 Addi-
tionally, a docker container with version-controlled dependencies to allow for reproducible
dataset creation is provided in the guacamol repository.77
8.2 Implementation details: Distribution-learning benchmarks
Validity The validity score is calculated as the ratio of valid molecules out of 10’000
generated molecules. Molecules are considered to be valid if their SMILES representation
can be successfully parsed by RDKit.
Uniqueness To calculate the uniqueness score, molecules are sampled from the generative
model until 10’000 valid molecules have been obtained. Duplicate molecules are identified
by identical canonical SMILES strings. The score is obtained as the number of different
canonical SMILES strings divided by 10’000.
Novelty The novelty score is calculated by generating molecules until 10’000 different
canonical SMILES strings are obtained, and computing the ratio of molecules not present in
the ChEMBL dataset.
Fre´chet ChemNet Distance (FCD) To generate the FCD score, a random subset of
10’000 molecules is selected from the ChEMBL dataset, and the generative model is sampled
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until 10’000 valid molecules are obtained. The FCD between both sets of molecules is
calculated with the FCD package available on GitHub,86 and the final score S is given by
S = exp(−0.2 · FCD) (2)
KL divergence For this task, the following physicochemical descriptors are calculated
with RDKit for both the sampled and the reference set: BertzCT, MolLogP, MolWt, TPSA,
NumHAcceptors, NumHDonors, NumRotatableBonds, NumAliphaticRings, and NumAromaticRings.
Furthermore, we calculate the distribution of maximum nearest neighbour similarities on
ECFP4 fingerprints for both sets. Then, the distribution of these descriptors is computed
via kernel density estimation (using the scipy package) for continuous descriptors, or as
a histogram for discrete descriptors. The KL divergence DKL,i is then computed for each
descriptor i, and is aggregated to a final score S via
S =
1
k
k∑
i
exp(−DKL,i), (3)
where k is the number of descriptors (in our case k = 9).
8.3 Implementation details: Goal-directed benchmarks
8.3.1 Formalism
In the goal-directed benchmarks discussed in this paper, raw molecular properties rarely
correspond to the molecule scores used for optimization. Instead, they are post-processed
by modifier functions that give more flexibility in how the final molecule score is computed,
and furthermore restrict scores to the interval [0, 1]. For the benchmarks discussed below,
we apply five different types of modifier functions. They are detailed in Appendix 8.3.4.
For many benchmarks the final molecule score corresponds to an average of multiple
contributions. For instance, the molecule score for the median molecules benchmarks is
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an average of two similarity scores (see below). Depending on the benchmark, the average
is calculated as the arithmetic mean or the geometric mean of the contributions. With a
geometric mean, all requirements (as given by the individual scoring functions) must be met,
at least partly. Otherwise, if one of the contributions has a score of zero, the final molecule
score will also be zero. With an arithmetic mean, the requirements are less strict, and a
molecule can still achieve a good score if one of its partial scores is zero.
The final benchmark score is calculated as a weighted average of the molecule scores.
For most of the benchmarks discussed below, the molecules with the best scores are given a
larger weight. This choice reflects the compromise that models should be able to deliver a
few molecules with top scores, but that they should also be able to generate many molecules
with satisfactory scores. For all the goal-directed benchmarks, we calculate one or several
average score for given numbers of top molecules, and then set the benchmark score to be
the mean of these average scores. For instance, many benchmarks consider the combination
of top-1, top-10 and top-100 scores, in which the benchmark score S is given by
S =
1
3
(
s1 +
1
10
10∑
i=1
si +
1
100
100∑
i=1
si
)
(4)
where s is a 100-dimensional vector of molecule scores si, 1 ≤ i ≤ 100, sorted in decreasing
order (i.e., si ≥ sj for i < j).
The suite of goal-directed benchmarks considered in this work is given in Appendix 8.3.2.
During evaluation, the duration of the benchmark, the number of calls to the scoring
function, and the internal similarity of the top molecules are captured in the results of each
goal-directed benchmark, in order to allow for more fine-grained analyses.
8.3.2 List of benchmarks
All the goal-directed benchmarks are listed in Table 3. More information about the scoring
functions and modifiers can be found in Appendices 8.3.3 and 8.3.4, respectively.
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Table 3: List of goal-directed benchmarks considered in this work. The molecule
score given by each benchmark is a combination of one or several contributions, with
their respective score modifiers. The column “Scoring” refers to the numbers of top
molecules to consider in the score calculation. For clarity, the following SMARTS and
SMILES strings were abbreviated in the table: s1 = CN(C=O)Cc1ccc(c2ccccc2)cc1,
s2 = [#7]-c1n[c;h1]nc2[c;h1]c(-[#8])[c;h0][c;h1]c12, s3 = [#7]-c1ccc2ncsc2c1,
s4 = CS([#6])(=O)=O, s5 = CCCOc1cc2ncnc(Nc3ccc4ncsc4c3)c2cc1S(=O)(=O)C(C)(C)C,
and s6 = [#6]-[#6]-[#6]-[#8]-[#6]~[#6]~[#6]~[#6]~[#6]-[#7]-c1ccc2ncsc2c1.
Benchmark name Scoring Mean Scoring function(s) Modifier
Celecoxxib rediscovery top-1 sim(Celecoxxib, ECFC4) None
Troglitazone rediscovery top-1 sim(Troglitazone, ECFC4) None
Thiothixene rediscovery top-1 sim(Thiothixene, ECFC4) None
Aripiprazole similarity top-1, top-10, top-100 sim(Aripiprazole, ECFC4) Thresholded(0.75)
Albuterol similarity top-1, top-10, top-100 sim(Albuterol, FCFC4) Thresholded(0.75)
Mestranol similarity top-1, top-10, top-100 sim(Mestranol, AP) Thresholded(0.75)
C11H24 top-159 isomer(C11H24) None
C9H10N2O2PF2Cl top-250 isomer(C9H10N2O2PF2Cl) None
Median molecules 1 top-1, top-10, top-100 geom.
sim(camphor, ECFC4) None
sim(menthol, ECFC4) None
Median molecules 2 top-1, top-10, top-100 geom.
sim(tadalafil, ECFC6) None
sim(sildenafil, ECFC6) None
Osimertinib MPO top-1, top-10, top-100 geom.
sim(osimertinib, FCFC4) Thresholded(0.8)
sim(osimertinib, ECFC6) MinGaussian(0.85, 2)
TPSA MaxGaussian(100, 2)
logP MinGaussian(1, 2)
Fexofenadine MPO top-1, top-10, top-100 geom.
sim(fexofenadine, AP) Thresholded(0.8)
TPSA MaxGaussian(90, 2)
logP MinGaussian(4, 2)
Ranolazine MPO top-1, top-10, top-100 geom.
sim(ranolazine, AP) Thresholded(0.7)
logP MaxGaussian(7, 1)
TPSA MaxGaussian(95, 20)
number of fluorine atoms Gaussian(1, 1)
Perindopril MPO top-1, top-10, top-100 geom.
sim(perindopril, ECFC4) None
number aromatic rings Gaussian(2, 0.5)
Amlodipine MPO top-1, top-10, top-100 geom.
sim(amlodipine, ECFC4) None
number rings Gaussian(3, 0.5)
Sitagliptin MPO top-1, top-10, top-100 geom.
sim(sitagliptin, ECFC4) Gaussian(0, 0.1)
logP Gaussian(2.0165, 0.2)
TPSA Gaussian(77.04, 5)
isomer(C16H15F6N5O) None
Zaleplon MPO top-1, top-10, top-100 geom.
sim(zaleplon, ECFC4) None
isomer(C19H17N3O2) None
Valsartan SMARTS top-1, top-10, top-100 geom.
SMARTS(s1, true) None
logP Gaussian(2.0165, 0.2)
TPSA Gaussian(77.04, 5)
Bertz Gaussian(896.38, 30)
Deco Hop top-1, top-10, top-100 arithm.
SMARTS(s2, true) None
SMARTS(s3, false) None
SMARTS(s4, false) None
sim(s5, PHCO) Thresholded(0.85)
Scaffold Hop top-1, top-10, top-100 arithm.
SMARTS(s2, false) None
SMARTS(s6, true) None
sim(s5, PHCO) Thresholded(0.75)
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The first six benchmarks fall into the rediscovery and similarity categories described in
Section 3.2. The molecules for these benchmarks are present in the holdout set considered
during dataset generation. The benchmarks C11H24 and C9H10N2O2PF2Cl are isomer bench-
marks. Note that the molecule C11H24 has 159 possible isomers when ignoring stereochem-
istry. Therefore, for this benchmark the final score is obtained from the top-159 molecule
scores. The two following benchmarks are median molecule benchmarks that aim to gen-
erate molecules mixing camphor and menthol, as well as tadalafil and sildenafil. The five
following benchmarks (Osimertinib MPO, Fexofenadine MPO, Ranolazine MPO, Perindopril
MPO, Amlodipine MPO), define objectives related to known drug molecules and trying to
fine-tune their structural or physicochemical properties. The Ranolazine MPO benchmark
uses a start population, comprising one single molecule (ranolazine). For the Sitagliptin
MPO benchmark, the models must generate molecules that are as dissimilar to sitagliptin as
possible, while keeping some of its properties. In the Zaleplon MPO benchmark, generative
models must find molecules that are similar to zaleplon but have a different molecular for-
mula. The valsartan SMARTS benchmark targets molecules containing a SMARTS pattern
related to valsartan while being characterized by physicochemical properties corresponding
to the sitagliptin molecule. Finally, the Scaffold Hop and Decorator Hop benchmarks aim to
maximize the similarity to a SMILES strings, while keeping or excluding specific SMARTS
patterns, mimicking the tasks of changing the scaffold of a compound while keeping specific
substituents, and keeping a scaffold fixed while changing the substitution pattern.
8.3.3 Scoring functions
Most of the scoring functions used in this work can readily be calculated from SMILES
strings or their underlying molecular graphs. The scoring functions for TPSA, logP, Bertz
and QED are calculated using the models contained in RDKit. The similarity, SMARTS,
and isomer scoring functions are explained in more detail in the following.
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Similarity scoring function The similarity scoring function (called “sim(x, y)” above)
refers to a scoring function calculating the similarity to a target molecule x. The score
corresponds to the Tanimoto similarity when considering the fingerprint y and is computed
with RDKit.
SMARTS scoring function The SMARTS scoring function (called “SMARTS(s, b)”
above) evaluates whether the SMARTS pattern s is present in the molecule to score or not.
b is a boolean value indicating whether the SMARTS pattern should be present (true) or
absent (false). When the pattern is desired, a score of 1 is returned if the SMARTS pattern
is found, else 0. When the pattern should be absent, the score will be 0 if the pattern is
found, else 1. The pattern recognition is computed with RDKit.
Isomer scoring function For the isomer benchmarks, the molecule score (called “isomer(x)”
above) is calculated as the geometric mean of the following contributions:
• For each element type present in the target molecular formula: the number of atoms
of this element type, modified by a Gaussian modifier. The Gaussian modifier has a
mean corresponding to the target number of atoms of this element type, and a standard
deviation of 1.0.
• The total number of atoms in the molecule, modified by a Gaussian modifier. The
Gaussian modifier has a mean corresponding to the total number of atoms of the
target molecular formula, and a standard deviation of 2.0.
For instance, for the target formula C11H24, the score s of a molecule m is given by:
s(m) =
(
exp
{
−
(nC(m)− 11)
2
2
}
· exp
{
−
(nH(m)− 24)
2
2
}
· exp
{
−
(ntot(m)− 35)
2
8
})1/3
(5)
where nC(m) and nH(m) refer to the number of carbon and hydrogen atoms present in m,
respectively, and ntot(m) is the total number of atoms in m.
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8.3.4 Score modifiers
For the benchmarks discussed above, we apply different types of modifier functions:
• Gaussian(µ, σ): The Gaussian modifier allows to target a specific value of some prop-
erty, while giving high scores when the underlying value is close to the target. It can
be adjusted with the mean µ and standard deviation σ of the underlying Gaussian
function.
• MinGaussian(µ, σ): The min Gaussian modifier corresponds to the right half of a
Gaussian function. Values smaller than µ are given full score, and values larger than
µ decrease continuously to zero.
• MaxGaussian(µ, σ): The max Gaussian modifier corresponds to the left half of a Gaus-
sian function. Values larger than µ are given full score, and values smaller than µ
decrease continuously to zero.
• Thresholded(t): With the thresholded modifier, full score is attributed to values above
a given threshold t. Values smaller than t decrease linearly to zero.
The effect of these four modifier functions is illustrated in Figure 4.
8.4 Baseline Models
Below, we give short descriptions of the baseline models involved in this work. Our imple-
mentations of the baseline models detailed here are available on GitHub.81
8.4.1 Random sampler
This baseline simply samples the requested number of molecules from the dataset at random.
It provides a lower bound for the goal directed benchmarks as no optimization is performed to
obtain the returned molecules, as well as an upper bound for two of the distribution learning
benchmarks, as the molecules returned are taken directly from the original distribution.
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Figure 4: Modifier functions used in this study.
8.4.2 Best in dataset
The goal of de novo molecular design is to explore unknown parts of chemical space, gen-
erating new compounds with better properties than the ones already known. This baseline
simply scores the entire dataset with the provided scoring function and returns the highest
scoring molecules. This effectively provides a lower bound for the goal directed benchmarks
as any good de novo method should be able to generate better molecules than the ones
provided during training or as a starting population. Distribution-learning benchmarks are
not applicable to this baseline.
8.4.3 SMILES GA
Genetic algorithms (GA) for de novo molecular design are well established technique.13,25
Yoshikawa et al. proposed a method that evolves string molecular representations using
mutations exploiting the SMILES context-free grammar.87
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For each goal-directed benchmark the 300 highest scoring molecules in the dataset are
selected as the initial population. Each molecule is represented by 300 genes. During each
epoch an offspring of 600 new molecules are generated by randomly mutating the population
molecules. After deduplication and scoring these new molecules are merged with the current
population and a new generation is selected by keeping the top scoring molecules overall.
This process is repeated 1000 times or until progress has stopped for 5 consecutive epochs.
Distribution-learning benchmarks do not apply to this baseline.
8.4.4 Graph GA
The second genetic algorithm baseline follows the implementation of Jensen88 in which
molecule evolution happens at the graph level.
For each goal-directed benchmark the 100 highest scoring molecules in the dataset are
selected as the initial population. During each epoch a mating pool of 200 molecules is sam-
pled with replacement from the population, using scores as weights. This pool may contain
many repeated specimens if their score is high. A new population of 100 is then generated by
iteratively choosing two molecules at random from the mating pool and applying a crossover
operation. With probability of 0.5 a mutation is also applied to the offspring molecule.
This process is repeated 1000 times or until progress has stopped for 5 consecutive epochs.
Distribution-learning benchmarks do not apply to this baseline.
8.4.5 Graph MCTS
The MCTS molecule generation procedure follows the implementation by Jensen.88 The
statistics used during sampling are computed on the GuacaMol dataset.
For this baseline no initial population is selected for the goal-directed benchmarks. Fol-
lowing the author’s parameters, each new molecule is generated by running 40 simulations,
starting from a CC base molecule, at each step 25 children are considered and the roll-out
stops when reaching 60 atoms. The best scoring molecule found during the roll-out is re-
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turned. A population of 100 molecules is generated at each epoch. This process is repeated
1000 times or until progress has stopped for 5 consecutive epochs.
For the distribution-learning benchmark the generation starts from a CC base molecule
and a new molecule is generated with the same parameters as for the goal oriented, the only
difference being that no scoring function is provided, so the first molecule to reach terminal
state is returned instead.
8.4.6 SMILES LSTM
The SMILES LSTM is a simple, yet powerful baseline model, consisting of a long-short term
memory (LSTM)35 neural network which predicts the next character of partial SMILES
strings.14 LSTM are more powerful than GRU networks, as they are able to learn a counting
mechanism.89 Combined with a simple hill-climb algorithm for optimization, which is an
off-policy policy gradient algorithm with binary rewards and can also be interpreted as
iterative fine-tuning, LSTM has recently been shown to perform as well as more sophisticated
reinforcement learning algorithms such as proximal policy optimization (PPO) or advantage
actor critic (A2C).49
The model used was an LSTM with 3 layers of hidden size of 1024. For the goal-directed
benchmarks 20 iterations of hill-climbing were performed, at each step the model generated
8192 molecules and the top scoring 1024 were used to fine-tune the model parameters. For
the distribution-learning benchmarks no fine tuning was done, the model simply generated
the requested number of molecules.
8.4.7 Variational Autoencoder
Variational encoder15 models learn a representation of molecules as latent vectors in a con-
tinuous space. The model architecture comprises an encoder that converts SMILES strings
to latent vectors, and a decoder that converts latent vectors back to SMILES strings. A
continuous-space representation of molecules enables sampling and property optimization
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in the latent space, after which the sample is decoded to produce the SMILES string of a
molecule of interest.
We evaluate an implementation of VAE available on the Internet.90 Only distribution-
learning benchmarks are supported by this implementation. The VAE was trained with the
hyperparameters previously optimized for the ZINC database.
8.4.8 Adversarial Autoencoder
The approach taken by adversarial autoencoders64 is related the latent vector encoding of
VAEs. For AAEs, the latent space is regularized in a way to enforce a distribution in the
latent space given by a prior.
We evaluate an implementation of AAE available on the Internet.90 Only distribution-
learning benchmarks are supported by this implementation. The AAE was trained with the
hyperparameters previously optimized for the ZINC database.
8.4.9 Objective-reinforced generative adversarial network
The objective-reinforced generative adversarial network (ORGAN)54 model architecture com-
bines a generator and a discriminator network for molecule generation.
We evaluate an implementation of ORGAN available on the Internet.90 Only distribution-
learning benchmarks are supported by this implementation. The ORGAN was trained with
the hyperparameters previously optimized for the ZINC database.
8.5 Results for trivial goal-directed benchmarks
Selecting adequate optimization objectives for benchmarking generative models is a chal-
lenging task. The main difficulty is to find tasks that are hard enough, i.e. objectives that
are not already satisfied by molecules in the training dataset. Otherwise, it is not possible
to demonstrate the usefulness of generative models — one must be able to assess whether
(and to what extent) they are better than virtual screening approaches.
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Table 4: List of trivial optimization objectives in the goal-directed formalism. Refer to Ap-
pendix 8.3 for details about the formalism and implementation of goal-directed benchmarks.
Benchmark name Scoring Mean Scoring function(s) Modifier
logP (target: -1.0) top-1, top-10, top-100 logP Gaussian(-1, 2)
logP (target: 8.0) top-1, top-10, top-100 logP Gaussian(8, 2)
TPSA (target: 150.0) top-1, top-10, top-100 TPSA Gaussian(150, 2)
CNS MPO top-1, top-10, top-100 arithm.
TPSA MinGaussian(90, 2)
TPSA MaxGaussian(40, 2)
number of hydrogen bond donors MinGaussian(0, 2)
logP MinGaussian(5.0, 2)
molecular weight MinGaussian(360, 2)
QED top-1, top-10, top-100 QED None
C7H8N2O2 top-100 isomer(C7H8N2O2) None
Pioglitazone MPO top-1, top-10, top-100 geom.
sim(pioglitazone, ECFP4) Gaussian(0, 0.1)
molecular weight Gaussian(356.447, 10)
number rotatable bonds Gaussian(2, 0.5)
Table 4 lists seven easily-optimizable benchmarks, and Table 5 shows the corresponding
scores achieved by the baseline models. The first three benchmarks in this table target given
values for physicochemical properties. All the models achieve near-perfect scores, including
“Best of dataset”. The models also get perfect scores for the CNS MPO benchmark, which
considers the CNS MPO score proposed by Pfizer.91 The QED benchmark aims to optimize
the “quantitative estimate of drug-likeness” (QED),92 an empirical measure of drug-likeness,
similar to Lipinski’s rule of 5.93 Even though optimization of drug-likeness alone is not a
particularly useful objective in drug discovery, it has been used in several publications as
a target for de novo molecular design (see, for instance, Refs. 15–17,55,57). The last two
benchmarks, C7H8N2O2 and Pioglitazone MPO, involve more complex scoring functions but
the generative models still achieve near-perfect scores for it.
Table 5: Results of the baseline models for the trivial goal-directed benchmarks.
Benchmark Best of dataset SMILES LSTM SMILES GA Graph GA Graph MCTS
logP (target: -1.0) 1.000 1.000 1.000 1.000 0.986
logP (target: 8.0) 1.000 1.000 1.000 1.000 0.980
TPSA (target: 150.0) 1.000 1.000 1.000 1.000 1.000
CNS MPO 1.000 1.000 1.000 1.000 1.000
QED 0.948 0.948 0.948 0.948 0.945
C7H8N2O2 0.972 1.000 0.992 0.993 0.851
Pioglitazone MPO 0.982 0.993 1.000 0.998 0.941
From these results, it is evident that such trivial benchmarks are not suitable for the
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assessment of generative models for de novo molecular design. The ChEMBL database
alone achieves excellent scores already and therefore these benchmarks cannot demonstrate
the advantage of generative models over pure virtual screening, and even less assess the
difference in performance for the models.
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